1. Introduction {#sec1}
===============

Both dementia and lower urinary tract symptoms (LUTS) are common problems in the elderly population, and they have a considerable effect on healthcare and social welfare systems \[[@B1], [@B2]\]. They increase the caregiver burden \[[@B3]\], dependency, care costs \[[@B4], [@B5]\], the incidence of skin damage \[[@B6]\], and anxiety and depression, and they reduce quality of life \[[@B7], [@B8]\].

The incident rate of LUTS is higher in those with dementia than without it \[[@B9]--[@B11]\]. Maintaining the continence is a complex mechanism that requires initiating the micturition reflex, responding to the sensation of a full bladder, and inhibiting the passage of urine \[[@B12]\]. Therefore, the progressive impairment of global brain function may have a substantial influence on the micturition control \[[@B7], [@B13]\].

Grant et al., however, found that the median interval between the onset of dementia and LUTS is only 9--11 months \[[@B9]\]. The clinical presentation implied that the functional decline in cognition and micturition may be concomitant. Moreover, recent researches demonstrated that LUTS may facilitate the progress of cardiovascular insults through multifactorial mechanism such as autonomic nervous dysfunction, affective disorders, or the adverse effects of drugs \[[@B14]\], and LUTS were identified as a significant predictor of acute cardiovascular events \[[@B15], [@B16]\]. Cardiovascular disease is a known risk factor of symptomatic or healthcare-seeking dementia \[[@B17], [@B18]\]. It is unclear whether LUTS are an early prodrome of declining global brain function or a risk factor of cognitive impairment.

We used Taiwan\'s National Health Insurance Research Database (NHIRD) for a cohort study to confirm the hypothesis that LUTS are associated with a higher risk of dementia.

2. Materials and Methods {#sec2}
========================

2.1. Data Source {#sec2.1}
----------------

Our data source is a randomly sampled cohort of 1 million people from the general population in NHIRD from 2000 to 2011. It is a representative cohort of Taiwan\'s population of 23 million. More than 99% of the citizens are the beneficiaries covered by National Health Insurance (NHI) for their medical expenditures. All the claim data of the healthcare services, including hospitalization and outpatient clinics, has been collected and encrypted in the NHIRD. Personal information in this dataset cannot be identified after encryption, and using the data must be authorized by the Taiwan Bureau of National Health Insurance (BNHI). Confidentiality assurances are addressed by following the data regulations of the BNHI. Our research protocol was approved by the institutional review board of Chi-Mei Medical Center.

2.2. Definition of LUTS {#sec2.2}
-----------------------

We identified patients who used outpatient services or who made hospitalization claims during the study period with the following categories of The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Codes: (a) storage symptoms, including hypertonicity of the bladder (ICD-9-CM code 596.51), stress urinary incontinence in women (625.6) and men (788.32), urgent incontinence (788.31), frequency and polyuria (788.4), nocturnal enuresis (788.36), nocturia (788.43), and mixed incontinence (788.33); (b) voiding symptoms, including retention of urine (788.2), splitting and slowing of urine stream (788.6), and post-void dribbling (788.35) \[[@B19]\]. We excluded the codes of benign prostatic hyperplasia that seem to be a kind of structural obstruction of urine flow outlet rather than nervous system degeneration.

2.3. Identifying Patients {#sec2.3}
-------------------------

We defined the recruitment period of 2000 to 2004 and identified patients with either of the following criteria as the LUTS group: (1) at least three outpatient service claims with the codes of LUTS at any clinics within one year after the first LUTS code; (2) any one single hospitalization with LUTS among the 5 principal claims diagnosis codes \[[@B19]\]. The date of the first LUTS code for every patient was designated as the index date of entry. We excluded those patients with any one time ICD-9-CM codes of dementia (290.0--290.4, 331.0, 331.82) before the index entry date. From patients without LUTS and free of dementia, a comparison group was assembled by matching LUTS patients with 3 non-LUTS patients on age and gender. The comorbidities of interest were diabetes mellitus (DM, ICD-9-CM code 250), hyperlipidemia (272), hypertension (HTN) (401--405), ischemic heart disease/coronary artery disease (CAD) (410--414), cerebrovascular disease (430--438), and atrial fibrillation (AF) (427.31).

2.4. Follow-Up and Outcome Measures {#sec2.4}
-----------------------------------

The major outcome of this study was the first diagnosis of dementia: senile and presenile dementia (ICD-9-CM codes 290.0-3), vascular dementia (290.4), Alzheimer\'s disease (331.0), and dementia with Lewy bodies/Parkinsonism with dementia (331.82). The diagnosis of dementia had to fit either of the following criteria: (1) at least three outpatient service claims with the codes of dementia at any clinics within one year after the first dementia code and (2) any one single hospitalization with dementia among the 5 principal claims diagnosis codes. The identified patients were followed up until death or the end of 2011.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Pearson\'s *χ* ^2^ test was used to estimate the differences in age group, gender, selected comorbidities (HTN, DM, CAD, hyperlipidemia, cerebrovascular disease, and AF), and dementia between the two cohorts. The difference in mean age between the LUTS and the non-LUTS groups was determined using the Student\'s *t*-test.

The dementia incidence rate was calculated by dividing the number of dementia patients by the total person years of both groups. Absolute risk estimates were calculated as rates per 10,000 person-years of observation. A Poisson regression with total person-years as an offset variable was used to calculate the incidence rate ratios of dementia. In addition, Kaplan-Meier curves and the log-rank test were used to describe the proportion of dementia-free patients and compare risk difference between the LUTS and the non-LUTS groups. Cox regression analysis was used to obtain adjusted hazard ratios (AHR) for potential confounding. SAS 9.3 (SAS Institute, Cary, NC) was used for all statistical analyses. Significance was set at *P* \< 0.05. Kaplan-Meier curves were plotted using STATA 12 (Stata Corp.*College Station*, TX).

3. Results {#sec3}
==========

We enrolled 6801 patients with LUTS in the LUTS^\[+\]^ study group and 20,403 patients in the LUTS^\[−\]^ control group. Age (mean: 67.29 ± 9.42 years) and gender distributions were comparable. The LUTS^\[+\]^ group had a significantly higher prevalence of HTN, DM, CAD, hyperlipidemia (marginally significant), AF, and cerebrovascular disease, which were known as comorbidities of LUTS in other studies \[[@B14], [@B15], [@B20]\]. These factors were adjusted for affecting reason. Significantly (*P* \< 0.0001) more LUTS^\[+\]^ group patients (741 (10.9%)) than LUTS^\[−\]^ group patients (1418 (6.9%)) had dementia during the follow-up. The median time span from the enrollment to the onset of dementia was significantly (*P* = 0.0002) shorter in the LUTS^\[+\]^ group than in the LUTS^\[−\]^ group ([Table 1](#tab1){ref-type="table"}).

The incidence rate ratio of dementia in the LUTS^\[+\]^ group to the LUTS^\[−\]^ group is 1.63 (95% confidence interval (CI) 1.49--1.78, *P* \< 0.0001) after adjusting age and gender ([Table 2](#tab2){ref-type="table"}). With the increase of age, the incidence rate of dementia rose as well, while the risk ratio of LUTS^\[+\]^ group to the LUTS^\[−\]^ group showed a reverse *J* curve with the peak risk ratio of 2.0 in the 60--70-year-old subgroup. LUTS had a consistent impact on higher risk of dementia in each subgroup stratified by different cardiovascular confounding factors. Kaplan-Meier survival curves showed that the patients in the LUTS^\[−\]^ group were less likely to have dementia than those in the LUTS^\[+\]^ group ([Figure 1](#fig1){ref-type="fig"}).

In a Cox regression model, age remained the most critical factor for the onset of dementia. CAD, hyperlipidemia, and AF had no significant impact on the risk of dementia after adjusting for all other confounders. LUTS were significantly associated with a comparatively greater risk of subsequent dementia (AHR = 1.61, 95% CI 1.47--1.76, *P* \< 0.0001) compared to other vascular risk factors including cerebrovascular disease (AHR = 1.43, 95% CI 1.26--1.61, *P* \< 0.0001) ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

In this nationwide population-based cohort study using data from Taiwan\'s NHIRD, LUTS were identified as a risk factor of dementia after adjusting for multiple comorbidities. It is noteworthy that the AHR of dementia in LUTS^\[+\]^ patients (1.61) was significantly higher than that of cerebrovascular disease in LUTS^\[+\]^ patients (1.43). To our knowledge, the finding that LUTS might be a prodrome of cognitive deficiency or a risk factor of dementia has seldom been mentioned in other research. Using a large nationwide population-based sample might give the finding persuasive statistical power.

The mechanism of micturition involves the cerebral cortex, the pons, the spinal cord, the autonomic and somatic nervous systems, the sensory system of the lower urinary tract, and the anatomical structure of the lower urinary tract itself \[[@B21]\]. Therefore, LUTS would occur if there was any error in the mechanism of micturition. Degeneration of global lobes, white matter lesions, and microvascular brain disease have been associated with LUTS \[[@B11], [@B12], [@B22]\]. Sakakibara et al. demonstrated that, in people with varying degrees of leukoaraiosis, LUTS might precede occurrence of cognitive disorder \[[@B23]\]. They also concluded that small vessel disease of the brain can cause incontinence, which maybe the initial manifestation of dementia in some patients \[[@B24]\]. It appeared that LUTS might be the early clinical symptom of the observed white matter changes and microvascular brain disease.

LUTS were associated with a higher vascular risk in other research \[[@B16], [@B25]\]. Lin et al. found that LUTS remained a significant predictor for acute cardiovascular events, mainly stroke \[[@B15]\]. Kotsoris et al. reported that urinary disturbances predated overt multi-infarct dementia by more than 5 years in up to 50% of patients \[[@B26]\]. This implied that LUTS may cause the decline of global brain function by increasing the rate of vascular injury. We found, however, a significantly higher risk of dementia in the LUTS^\[+\]^ group after adjustment for confounding effects by cerebrovascular disease and other cardiovascular risk factors. Thus, the role of LUTS in the pathogenesis of dementia might be complex.

Disorders of autonomic nervous system are also associated with LUTS \[[@B27], [@B28]\]. The most common example is diabetes, which causes LUTS by autonomic neuropathy and is also involved in the decline of cognitive function \[[@B29]\]. The central control for the autonomic system includes the insular cortex, amygdala, hypothalamus, periaqueductal gray, parabrachial nucleus, nucleus of the solitary tract, and medulla \[[@B30]\]. Several components of the central autonomic networks are affected and characterized by the presence of intracellular inclusions containing *α*-synuclein in neurodegenerative disorders, such as multiple system atrophy and Lewy body disorders \[[@B30], [@B31]\]. Braak proposed that an immunocytochemical analysis might indicate preclinical neuropathological degeneration of autonomic control in the insular cortex and the brainstem before the onset of obvious cognitive dysfunction in individuals with Alzheimer\'s disease \[[@B32]\]. Collins et al. also reported that participants with mild cognitive impairment were about 6 times more likely than controls without cognitive impairment to have autonomic dysfunction \[[@B33]\]. LUTS, which result from autonomic dysfunction, may therefore be indicative of early stage of cognition decline and consequent dementia.

Pharmacological treatment for LUTS involves using antimuscarinic or anticholinergic agents, which have adverse effects on cognitive function \[[@B34], [@B35]\]. The change in cognitive function is caused by the drugs\' ability to cross the blood-brain barrier and block muscarinic and cholinergic receptors in the central nervous system (CNS). Results from electroencephalographic data suggest that oxybutynin has a greater effect on central nervous system than trospium and tolterodine \[[@B36]\]. The elderly patients who take these antimuscarinic and anticholinergic agents as therapy for LUTS may have a higher risk of dementia.

LUTS negatively affect quality of life and cause depression, anxiety, and social withdrawal \[[@B7], [@B8], [@B37]\]. Thor et al. concluded that the monoamine neurotransmitters serotonin (5-HT) and noradrenaline (NA) are involved in the physiological processes of LUTS and major depressive disorder \[[@B37]\]. Mild worry symptoms and anxiety can predict declines in learning and memory \[[@B38], [@B39]\]. Geda et al. also suggested that agitation, anxiety, irritability, and depression increased the risk for later cognitive impairment \[[@B40]\]. For this reason, LUTS may increase the risk of cognitive dysfunction by causing neuropsychiatric disorders.

The main strength of this cohort study is the large size of Taiwan\'s nationwide NHIRD random sample from the general population. However, our study had some limitations. First, the lack of data from the population in low socioeconomic status without continuous health insurance coverage may lead to the under-ascertainment of dementia. However, the steady and high percentage of citizens coverage (\>98% since 2002 and 99.51% in 2011) \[[@B41]\] by NHI made the underestimation much less marked. Second, we could neither classify the clinical severity or manifestations of LUTS and dementia nor demonstrate the linkage between subtypes of LUTS and dementia. Third, we lacked data about drugs and psychosocial connection which may have affected both LUTS and cognition. Thus, additional research is needed to identify the mechanism that led to the results in our study.

In conclusion, LUTS increase the risk of dementia in the aging population. To prevent or reduce the predisposing factors of cognitive impairment, early screening and timely intervention, such as nonpharmacological therapy for the elderly patients with LUTS, should be considered. Additional investigations are necessary to evaluate the association of the clinical severity of disease, the connection between different types of LUTS and dementia, the effect of pharmacological therapy, and the psychosocial connection between LUTS and cognitive dysfunction.
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###### 

Demographic information.

                            Non-LUTS (*n* = 20403)   LUTS (*n* = 6801)   *P* ^\*^
  ------------------------- ------------------------ ------------------- ----------
  Age (years) (mean ± SD)   67.29 ± 9.42             67.29 ± 9.42        0.9994
  Age (years)                                                             
   50\~60                   5171 (25.34)             1723 (25.33)        1.0000
   60\~70                   6491 (31.81)             2164 (31.82)        
   70\~80                   7071 (34.66)             2356 (34.64)        
   ≥80                      1670 (8.19)              558 (8.20)          
  Gender                                                                  
   Male                     11469 (56.21)            3823 (56.21)        1.0000
   Female                   8934 (43.79)             2978 (43.79)        
  Hypertension                                                            
   Yes                      6949 (34.06)             2420 (35.58)        0.0220
   No                       13454 (65.94)            4381 (64.42)        
  Diabetes                                                                
   Yes                      2985 (14.63)             1141 (16.78)        \<0.0001
   No                       17418 (85.37)            5660 (83.22)        
  Coronary artery disease                                                 
   Yes                      2408 (11.80)             907 (13.34)         0.0008
   No                       17995 (88.20)            5894 (86.66)        
  Hyperlipidemia                                                          
   Yes                      1576 (7.72)              574 (8.44)          0.0582
   No                       18827 (92.28)            6227 (91.56)        
  Cerebrovascular disease                                                 
   Yes                      1591 (7.80)              707 (10.40)         \<0.0001
   No                       18812 (92.20)            6094 (89.60)        
  Atrial fibrillation                                                     
   Yes                      229 (1.12)               101 (1.49)          0.0180
   No                       20174 (98.88)            6700 (98.51)        
  Time to dementia (year)                                                 
   Median (IQR)             4.97 (2.57--7.07)        4.37 (1.93--6.61)   0.0002
  Dementia                                                                
   Yes                      1418 (6.95)              741 (10.90)         \<0.0001
   No                       18985 (93.05)            6060 (89.10)        

^\*^It is determined using Student\'s *t*-test or the Wilcoxon test for continuous variables and the *χ* ^2^ test for categorical variables. Data are number (%). LUTS: lower urinary tract symptoms; SD: standard deviation; IQR: interquartile range.

###### 

Incidence of dementia in LUTS patients.

                            Non-LUTS (*n* = 20403)   LUTS (*n* = 6801)   Adjusted IRR^\*^ (95% CI)   *P*                                                                                  
  ------------------------- ------------------------ ------------------- --------------------------- ----------- ---------- --------- -------------- ------------ ----------------------- --------------
  Total                     **20403**                **1418**            **182760.38**               **77.59**   **6801**   **741**   **59392.21**   **124.76**   **1.63 (1.49--1.78)**   **\<0.0001**
  Age (years)                                                                                                                                                                              
   50\~60                   5171                     67                  47695.02                    14.05       1723       36        15834.09       22.74        1.62 (1.08--2.43)       0.0198
   60\~70                   6491                     284                 59208.05                    47.97       2164       185       19289.33       95.91        2.00 (1.66--2.41)       \<0.0001
   70\~80                   7071                     804                 61574.10                    130.57      2356       396       19740.50       200.60       1.54 (1.37--1.74)       \<0.0001
   ≥80                      1670                     263                 14283.21                    184.13      558        124       4528.29        273.83       1.49 (1.20--1.84)       \<0.0003
  Gender                                                                                                                                                                                   
   Male                     11469                    814                 101731.17                   80.02       3823       403       33165.82       121.51       1.52 (1.36--1.72)       \<0.0001
   Female                   8934                     604                 81029.20                    74.54       2978       338       26226.39       128.88       1.76 (1.54--2.01)       \<0.0001
  Hypertension                                                                                                                                                                             
   No                       13454                    809                 121784.75                   66.43       4381       393       39480.85       99.54        1.49 (1.32--1.69)       \<0.0001
   Yes                      6949                     609                 60975.62                    99.88       2420       348       19911.36       174.78       1.81 (1.59--2.06)       \<0.0001
  Diabetes                                                                                                                                                                                 
   No                       17418                    1156                156414.36                   73.91       5660       585       49944.80       117.13       1.62 (1.47--1.79)       \<0.0001
   Yes                      2985                     262                 26346.02                    99.45       1141       156       9447.41        165.13       1.62 (1.33--1.98)       \<0.0001
  Coronary artery disease                                                                                                                                                                  
   No                       17995                    1180                161652.69                   73.00       5894       614       51908.31       118.29       1.66 (1.50--1.83)       \<0.0001
   Yes                      2408                     238                 21107.69                    112.76      907        127       7483.90        169.70       1.48 (1.19--1.84)       0.0004
  Hyperlipidemia                                                                                                                                                                           
   No                       18827                    1311                169048.45                   77.55       6227       665       54693.83       121.59       1.58 (1.44--1.74)       \<0.0001
   Yes                      1576                     107                 13711.93                    78.03       574        76        4698.38        161.76       2.16 (1.61--2.91)       \<0.0001
  Cerebrovascular disease                                                                                                                                                                  
   No                       18812                    1220                169158.45                   72.12       6094       607       53732.30       112.97       1.59 (1.45--1.76)       \<0.0001
   Yes                      1591                     198                 13601.92                    145.57      707        134       5659.92        236.75       1.66 (1.33--2.07)       \<0.0001
  Atrial fibrillation                                                                                                                                                                      
   No                       20174                    1395                180772.73                   77.17       6700       719       58568.11       122.76       1.61 (1.47--1.76)       \<0.0001
   Yes                      229                      23                  1987.65                     115.72      101        22        824.10         266.96       2.27 (1.26--4.06)       0.0061

CI: confidence interval; IR: incidence rate, per 1000 person-years; IRR: incidence rate ratio; LUTS: lower urinary tract symptoms; PY: person-years.

^\*^The IRR was adjusted by age and gender.

###### 

Cox proportional hazards regression analyses for the risk of dementia stratified by confounding factors.

                            Crude hazards (95% CI)   *P*        Adjusted hazards^\*^ (95% CI)   *P*
  ------------------------- ------------------------ ---------- ------------------------------- ----------
  LUTS                                                                                           
   No                       1.00 (ref.)                         1.00 (ref.)                      
   Yes                      1.61 (1.47--1.76)        \<0.0001   1.61 (1.47--1.76)               \<0.0001
  Age (years)                                                                                    
   50\~60                   1.00 (ref.)                         1.00 (ref.)                      
   60\~70                   3.69 (2.98--4.56)        \<0.0001   3.65 (2.94--4.52)               \<0.0001
   70\~80                   9.11 (7.45--11.14)       \<0.0001   9.02 (7.36--11.07)              \<0.0001
   ≥80                      12.71 (10.23--15.80)     \<0.0001   12.40 (9.94--15.44)             \<0.0001
  Gender                                                                                         
   Male                     1.00 (ref.)                         1.00 (ref.)                      
   Female                   0.97 (0.90--1.06)        0.5509     1.30 (1.19--1.41)               \<0.0001
  Hypertension                                                                                   
   No                       1.00 (ref.)                         1.00 (ref.)                      
   Yes                      1.59 (1.46--1.73)        \<0.0001   1.12 (1.02--1.23)               0.0136
  Diabetes                                                                                       
   No                       1.00 (ref.)                         1.00 (ref.)                      
   Yes                      1.38 (1.24--1.54)        \<0.0001   1.13 (1.01--1.27)               0.0286
  Coronary artery disease                                                                        
   No                       1.00 (ref.)                         1.00 (ref.)                      
   Yes                      1.52 (1.36--1.70)        \<0.0001   1.03 (0.92--1.16)               0.5793
  Hyperlipidemia                                                                                 
   No                       1.00 (ref.)                         1.00 (ref.)                      
   Yes                      1.12 (0.97--1.31)        0.1304     1.01 (0.86--1.18)               0.9046
  Cerebrovascular disease                                                                        
   No                       1.00 (ref.)                         1.00 (ref.)                      
   Yes                      2.10 (1.87--2.36)        \<0.0001   1.43 (1.26--1.61)               \<0.0001
  Atrial fibrillation                                                                            
   No                       1.00 (ref.)                         1.00 (ref.)                      
   Yes                      1.81 (1.35--2.44)        \<0.0001   1.07 (0.80--1.45)               0.6457

^\*^The model was adjusted by the variables which were listed above.

CI: confidence interval; LUTS: lower urinary tract symptoms; ref.: reference.
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